TG Therapeutics Inc (TGTX)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $9.49B
Last updated: Nov 17, 2026 at 4:41 PM ET
TG Therapeutics Inc (TGTX) Statistics
TG Therapeutics (TGTX) has a market cap of $9.49B and an enterprise value of $9.75B. Revenue grew 76.08% over the last 12 months from the 12 months before. It kept 55.22% of revenue as net income over the last 12 months.
Total Valuation
Enterprise value is 2.77% above the market cap, as debt exceeds cash.
| Market Cap | $9.49B |
|---|---|
| Enterprise Value | $9.75B |
| Latest price (Nov 17, 2026) | $62.71 |
Key Dates
The next earnings report is expected on Jan 11, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Jan 11, 2027 (expected) |
|---|---|
| Last Earnings Date | Nov 9, 2026 |
| Fiscal Year End | December |
Valuation Ratios
Sales and book value multiples are 11.1x and 14.7x.
| P/E Ratio | 87.1x |
|---|---|
| Forward P/E | 61.2x |
| P/S Ratio | 11.1x |
| Forward P/S | 9.5x |
| P/B Ratio | 14.7x |
| P/FCF Ratio | 511.4x |
| P/OCF Ratio | 530.7x |
| PEG Ratio | 8.4 |
Enterprise Valuation
Counting debt and cash, the company is valued at 61.9x EBITDA and 526.5x free cash flow.
| EV / Earnings | 22.1x |
|---|---|
| EV / Sales | 12.2x |
| EV / EBITDA | 61.9x |
| EV / EBIT | 65.8x |
| EV / FCF | 526.5x |
Price Statistics
The stock is up 102.29% over 52 weeks and trades 10.08% above its 50-day average.
| Beta (1Y) | 0.70 |
|---|---|
| 52-Week Change | +102.29% |
| 1-Month Change | +17.65% |
| 3-Month Change | +21.32% |
| 6-Month Change | +59.04% |
| 5-Year Change | +95.96% |
| 10-Year Change | +1043.55% |
| Total Return (1Y) | +102.29% |
| Total Return (3Y CAGR) | +73.18% |
| Total Return (5Y CAGR) | +20.34% |
| Return vs SPY (1Y) | +89.37% |
| Max Drawdown (1Y) | -21.83% |
| Max Drawdown (3Y) | -42.01% |
| Sharpe Ratio (1Y) | 1.54 |
| Correlation with SPY (1Y) | 0.21 |
| 50-Day Average | $56.97 |
| 200-Day Average | $45.71 |
| 52-Week Range | $26.76 to $68.03 |
| RSI (14 Days) | 59.2 |
| Average Volume (20 Days) | 2.14M |
The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 4.27x current liabilities, and total debt is 1.23x shareholder equity.
| Current Ratio | 4.27x |
|---|---|
| Quick Ratio | 3.72x |
| Debt / Equity | 1.23x |
| Debt / EBITDA | 5.04x |
| Debt / FCF | 42.88x |
| Interest Coverage | 3.18x |
Returns and Efficiency
Return on invested capital is 10.99% over the last 12 months, against a 5-year average of -36.86%.
| Return on Equity (ROE) | 73.08% |
|---|---|
| Return on Assets (ROA) | 26.93% |
| Return on Invested Capital (ROIC) | 10.99% |
| Return on Capital Employed (ROCE) | 10.81% |
| ROE (5Y Average) | -88.28% |
| ROA (5Y Average) | -31.47% |
| ROIC (5Y Average) | -36.86% |
| Asset Turnover | 0.68x |
| Inventory Turnover | 1.02x |
| Receivables Turnover | 2.01x |
| Cash Conversion Cycle | 70 days |
Scores
TGTX has an Altman Z-Score of 5.68, in the safe zone above 2.99, and a Piotroski F-Score of 5 of 9, in the average band of 3 to 7.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | 5.68 |
|---|---|
| Altman Z Zone | Safe |
| Piotroski F-Score | 5 of 9 |
| Piotroski Strength | Average |
Income Statement
Revenue was $799.54M over the last 12 months.
| Revenue | $799.54M |
|---|---|
| Revenue Growth (YoY) | +76.08% |
| Gross Profit | $658.60M |
| Operating Income | $136.33M |
| Pretax Income | $101.60M |
| Net Income | $441.49M |
| EBITDA | $147.90M |
| EBIT | $148.24M |
| Reported EPS (TTM) | $0.72 |
Trailing 12 months through Jun 30, 2026.
Balance Sheet
Shareholder equity funds 36.83% of the $1.64B in total assets.
| Cash and Equivalents | $482.57M |
|---|---|
| Total Debt | $745.39M |
| Net Debt | $262.81M |
| Net Debt Per Share | $1.85 |
| Working Capital | $877.19M |
| Shareholder Equity | $604.08M |
| Book Value Per Share | $4.26 |
| Total Assets | $1.64B |
| Total Liabilities | $1.04B |
Balance sheet as of Jun 30, 2026.
Cash Flow
After $491.00K of capital spending, operating cash flow left $17.39M of free cash flow.
| Operating Cash Flow | $17.88M |
|---|---|
| Capital Expenditures | $491.00K |
| Free Cash Flow | $17.39M |
| FCF Per Share | $0.11 |
| Depreciation and Amortization | $663.00K |
Trailing 12 months through Jun 30, 2026.
Margins
The operating margin is 17.05%.
| Gross Margin | 82.37% |
|---|---|
| Operating Margin | 17.05% |
| Pretax Margin | 12.71% |
| Net Margin | 55.22% |
| EBITDA Margin | 18.50% |
| EBIT Margin | 18.54% |
| FCF Margin | 2.17% |
| Gross Margin (5Y Average) | 90.82% |
Growth
Revenue grew 504.86% a year over 3 years.
| Revenue Growth (3Y CAGR) | +504.86% |
|---|---|
| Revenue Growth (5Y CAGR) | +426.73% |
| Book Value Per Share Growth (2Y CAGR) | +90.40% |
| Tangible Book Per Share Growth (2Y CAGR) | +90.40% |
Dividends and Yields
TGTX does not pay a dividend. Its free cash flow yield is 0.20%.
| Earnings Yield | 1.15% |
|---|---|
| FCF Yield | 0.20% |
| Buyback Yield | 2.00% |
| Shareholder Yield | 2.00% |
Stock Splits
The last split was a 1-for-56 reverse split on Apr 30, 2012.
| Last Split Date | Apr 30, 2012 |
|---|---|
| Split Type | Reverse split |
| Split Ratio | 1:56 |
Peer Position
Against 3 similar companies, TGTX has the highest P/E.
P/E RatioPeer median 39.5x
P/S RatioPeer median 8.8x
ROICPeer median -21.06%
Revenue Growth (Trailing 4 Quarters, YoY)Peer median +37.67%
| P/E Ratio | 87.1x vs 39.5x median |
|---|---|
| P/S Ratio | 11.1x vs 8.8x median |
| ROIC | 10.99% vs -21.06% median |
| Revenue Growth (Trailing 4 Quarters, YoY) | +76.08% vs +37.67% median |
Analyst Forecast
Consensus estimates put revenue growth at 47.69% and EPS growth at 125.98% a year over the next 2 fiscal years.
| Revenue Growth Forecast (2Y CAGR) | +47.69% |
|---|---|
| EPS Growth Forecast (2Y CAGR) | +125.98% |
Price Target
Analyst price targets are part of paid GNG plans. See plans
GNG Valuation
| GNG view | Fairly valued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About TGTX
What is TGTX's market cap?
TG Therapeutics has a market cap of $9.49B. Its enterprise value, which adds debt and subtracts cash, is $9.75B.
What is TGTX's P/E ratio?
TG Therapeutics has a trailing P/E ratio of 87.1x and a forward P/E of 61.2x.
How many shares of TGTX are outstanding?
TG Therapeutics has 141.77M shares outstanding. The count is down 3.39% from a year earlier.
Does TGTX pay a dividend?
No. TG Therapeutics does not pay a dividend.
How much debt does TGTX have?
TG Therapeutics has $745.39M of total debt and $482.57M of cash and equivalents, a net debt position of $262.81M.
TGTX pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Valuation, Competitors